1. Home
  2. FBP vs LQDA Comparison

FBP vs LQDA Comparison

Compare FBP & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First BanCorp. New

FBP

First BanCorp. New

N/A

Current Price

$19.97

Market Cap

3.6B

Sector

Finance

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$35.39

Market Cap

3.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FBP
LQDA
Founded
1948
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.1B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
FBP
LQDA
Price
$19.97
$35.39
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$24.13
$39.82
AVG Volume (30 Days)
986.4K
1.8M
Earning Date
04-28-2026
06-15-2026
Dividend Yield
3.87%
N/A
EPS Growth
18.78
51.81
EPS
2.15
N/A
Revenue
$1,255,034,000.00
$158,320,000.00
Revenue This Year
$15.10
$208.46
Revenue Next Year
$4.56
$27.44
P/E Ratio
$9.58
N/A
Revenue Growth
2.38
1031.18
52 Week Low
$16.40
$11.26
52 Week High
$23.43
$46.67

Technical Indicators

Market Signals
Indicator
FBP
LQDA
Relative Strength Index (RSI) 29.53 49.39
Support Level $19.46 $30.48
Resistance Level $22.28 $36.07
Average True Range (ATR) 0.58 2.33
MACD -0.26 0.27
Stochastic Oscillator 5.11 70.77

Price Performance

Historical Comparison
FBP
LQDA

About FBP First BanCorp. New

First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: